Corcept Therapeutics Incorporat (CORT) Stock Price & How to Invest

Corcept Therapeutics is a commercial-stage pharmaceutical company focused on disorders driven by excess cortisol activity. Its foundation is Korlym (mifepristone), a glucocorticoid receptor modulator approved for hypercortisolism (Cushing's syndrome), which generated the bulk of its ~$761 million in 2025 revenue. The company has spent years building physician awareness that hypercortisolism is more common than historically recognized, driving record new-patient starts, and it is expanding beyond a single product: the FDA approved Lifyorli (relacorilant) for platinum-resistant ovarian cancer in March 2026, and Corcept resubmitted a New Drug Application for relacorilant in Cushing's syndrome in June 2026.

The investment picture is unusual for biotech: Corcept is consistently profitable, carries zero debt, and held roughly $515 million in cash and investments as of March 2026. Management raised full-year 2026 revenue guidance to a $950 million to $1.05 billion range. The counterweight is concentration and legal risk. A court ruling cleared a path for Teva's generic version of Korlym, threatening the franchise that still funds nearly everything, so the bull case rests on relacorilant approvals and the oncology pipeline replacing and outgrowing branded Korlym before generic erosion bites.

Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. Relacorilant approval is not guaranteed, as evidenced by an earlier FDA complete response letter before the June 2026 resubmission. Teva has also raised antitrust-style allegations about Corcept's distribution and patent practices, adding litigation overhang. The stock trades at a rich trailing earnings multiple, so any disappointment in guidance, approvals, or generic timing can drive sharp drawdowns, and the oncology launch is early and unproven at scale.

5 analysts publish price targets on CORT, averaging $141.00 against a $113.38 price as of September 2026, or +24.4%. The published targets run from $50.00 to $165.00, a wide spread, and the ratings split 4 buy, 0 hold, 1 sell. Over the last six months there have been 11 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CORT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Corcept Therapeutics Incorporat. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Cushing's / hypercortisolism growth runway. Corcept has spent years educating endocrinologists that hypercortisolism is underdiagnosed, and that effort is showing up in record new-patient starts and record new prescribers. The most optimistic published target, $165.00, assumes this works close to its best case.

The case against. Revenue concentration is the defining risk: Korlym still drives the overwhelming majority of sales, and a court ruling has cleared a path for Teva's generic mifepristone, which could erode the flagship franchise faster than the new products scale. The most pessimistic target, $50.00, is roughly what CORT is worth if this bites instead.

Read the full bull and bear case on CORT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Corcept Therapeutics Incorporat (CORT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Corcept Therapeutics Incorporat's investor relations page or your broker.

• Revenue (TTM): ~$770M
• FY2025 revenue: ~$761M
• FY2026 revenue guidance: ~$950M to $1.05B
• Market cap: ~$9.4B
• P/E (TTM): ~50x
• Cash & investments / debt: ~$515M / no debt

Corcept is profitable on a full-year basis but posted a Q1 2026 net loss of roughly $32 million as it ramped Lifyorli launch spending (SG&A near $145 million, R&D near $66 million). The trailing P/E near 50x reflects a growth-and-optionality premium rather than a value multiple. The zero-debt balance sheet and half-billion-dollar cash cushion give it flexibility to fund launches and litigation internally.

If you want CORT exposure as part of a larger bundle rather than directly, these ETFs hold it meaningfully. Weights are approximate and refresh quarterly.

Other names that sit close to CORT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get CORT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it (SLYG), which spreads the position across many companies. Or build it into a focused thematic portfolio, so CORT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CORT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

CORT is a profitable single-franchise specialty pharma trying to diversify into oncology and a next-generation Cushing's drug, with generic-Korlym risk as the central overhang.

Whether CORT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CORT a buy or a sell?, and where the stock could go from here in the CORT stock forecast.

For income investors, whether CORT pays a dividend and how the payout looks is covered in does CORT pay a dividend? And to weigh CORT against a peer, read the full side-by-side comparisons: CORT vs TEVA and CORT vs AZN.